Medical Technology
BioIntel Editorial Team
BioIntel Editorial Team is a group of domain experts and writers focused on biotech, healthcare, and AI. They deliver original, high-signal coverage tailored for industry professionals, investors, and researchers. With a neutral and independent voice, the team transforms complex developments into clear, actionable insights.
Recent posts
Regulatory & Policy
Kaiser Permanente to Pay $556M to Settle Medicare Advantage Fraud Allegations
Biopharmaceutical Industry
Takeda’s $1.2 Billion Bispecific Antibody Deal: Potential Game-Changer in Oncology Drug Development
Biopharmaceutical Industry
JPM 2026 Day 4 Highlights: Regeneron Insights, IPO Forecasts, and J&J Spotlight
Biopharmaceutical Industry
JPM Day 3: Rare Disease in the Spotlight as 2026 Promises Key Milestones
Regulatory & Policy
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Stalls in Senate
Biotech Innovation
Biomedical Student Enrollment Increases Despite Funding Challenges in 2025
Regulatory & Policy
Pharmacy Compounder Files Antitrust Lawsuit Against Eli Lilly and Novo Nordisk in Weight Loss Drug Market
Healthcare Investment
Private Equity's Healthcare Boom: Increasing Investments and Intensifying Competition
Healthcare Investment
JPM26: Sanofi’s Strategy to Capitalize on Vaccine Sector Volatility Amid Political Rhetoric
Regulatory & Policy
US Overdose Deaths Show Decline Throughout Most of 2025, Offering Hope Amid Epidemic
Regulatory & Policy